Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-mannosidase 2x (MAN2A2) is a Golgi-resident glycosidase enzyme that catalyzes the committed step in the maturation of complex N-glycans, converting high-mannose structures to complex N-glycans by hydrolyzing specific mannose residues[1][2][6]. This activity is essential for proper protein folding, trafficking, and—specifically in the testis—for cell–cell adhesion processes critical for spermatogenesis. Genetic disruption of MAN2A2 alters glycan structures, causing defects in protein processing and cellular adhesion, and is associated with several reproductive and developmental diseases such as various forms of spermatogenic failure, Hirschsprung disease, and congenital bilateral absence of the vas deferens[1][2]. The enzyme is predicted to be membrane-bound and localized to the Golgi apparatus[2][3][6]. While MAN2A2 is considered an enzyme of therapeutic interest based on gene-function and disease-association studies, no small-molecule inhibitors or drugs are currently known to target it directly[2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-mannosidase 2x (MAN2A2).